Small Molecules in the Treatment of Psoriasis
- PMID: 26255795
- DOI: 10.1002/ddr.21263
Small Molecules in the Treatment of Psoriasis
Abstract
Preclinical Research Psoriasis is an inflammatory systemic skin disease that affects various parts of the body requiring long-term management due to its chronic nature. Available treatment options include topical, systemic or biological therapies, which have long-term limitations associated to toxicity, tolerability and risk for adverse effects requiring its intermittent use and close monitoring. Small molecules modulate proinflammatory cytokines, selectively inhibit signaling pathways and showing potential to treat inflammatory diseases in patients not responding to conventional treatments. Presently, small molecules available are phosphodiesterase 4 inhibitors or Janus kinase inhibitors. Other small molecules under development for psoriasis include fumaric acid esters, amygdalin analogs, protein kinase C inhibitors, mitogen-activated protein kinase inhibitors, spleen protein kinase inhibitors, other tyrosine kinase inhibitors, sphingosine 1-phosphate receptor agonists, and A3 adenosine receptor agonists. These new treatment options represent important advances in the development of specific drugs to respond to the goals of treatment and improve patient quality of life.
Keywords: apremilast; psoriasis; tofacinib.
© 2015 Wiley Periodicals, Inc.
Similar articles
-
New drugs and treatment targets in psoriasis.Acta Derm Venereol. 2015 Feb;95(2):133-9. doi: 10.2340/00015555-1931. Acta Derm Venereol. 2015. PMID: 25111317 Review.
-
New therapies under development for psoriasis treatment.Curr Opin Pediatr. 2013 Aug;25(4):480-7. doi: 10.1097/MOP.0b013e328362c3f6. Curr Opin Pediatr. 2013. PMID: 23838833 Review.
-
Amygdalin analogs for the treatment of psoriasis.Future Med Chem. 2013 May;5(7):799-808. doi: 10.4155/fmc.13.27. Future Med Chem. 2013. PMID: 23651093 Review.
-
Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.Eur J Dermatol. 2016 Jan-Feb;26(1):3-8. doi: 10.1684/ejd.2015.2663. Eur J Dermatol. 2016. PMID: 26552963 Review.
-
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Expert Rev Clin Immunol. 2016;12(3):237-49. doi: 10.1586/1744666X.2016.1134319. Expert Rev Clin Immunol. 2016. PMID: 26692125
Cited by
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535. doi: 10.1002/14651858.CD011535.pub4. PMID: 31917873 Free PMC article. Updated.
-
New developments in the molecular treatment of ichthyosis: review of the literature.Orphanet J Rare Dis. 2022 Jul 15;17(1):269. doi: 10.1186/s13023-022-02430-6. Orphanet J Rare Dis. 2022. PMID: 35840979 Free PMC article. Review.
-
Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson.J Immunol Res. 2018 May 15;2018:2310970. doi: 10.1155/2018/2310970. eCollection 2018. J Immunol Res. 2018. PMID: 29862305 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated. Review.
-
A computational multi-targeting approach for drug repositioning for psoriasis treatment.BMC Complement Med Ther. 2021 Jul 5;21(1):193. doi: 10.1186/s12906-021-03359-2. BMC Complement Med Ther. 2021. PMID: 34225727 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
